Search for a doctor

Kambiz Kalantari, M.D.

  1. Nephrologist

Publications

  1. Sullivan M, Mead-Harvey C, Sartori-Valinotti JC, Kalantari K, Kusne YN, Patnaik M, Mangaonkar AA, Go R, Montes D, Reichard K, Olteanu H, Bois M, Hines A, Warrington K, Koster MJ. Vasculitis associated with VEXAS syndrome. Rheumatology (Oxford). 2024 Oct 11 [Epub ahead of print]
    View PubMed
  2. Kalantari K, Sullivan MM, Hernandez LPH, Bu L, Cornell LD, Nasr SH, Fervenza FC, Montes D, Mangaonkar AA, Go RS, Kusne YN, Patnaik MM, Lasho TL, Olteanu H, Reichard KK, Warrington KJ, Koster MJ. Acute kidney injury, an underrecognized feature of VEXAS syndrome. Rheumatology (Oxford). 2024 Aug 26 [Epub ahead of print]
    View PubMed
  3. Kalantari K, Rosner MH. Recent advances in the pharmacological management of sepsis-associated acute kidney injury Expert Rev Clin Pharm. 2021; 14(11):1401-1411.
  4. Kalantari K, Swaminathan S. Use of Gadolinium in Individuals with Reduced Kidney Function. Clin J Am Soc Nephrol. 2021 Feb 8; 16 (2):304-306 Epub 2021 Jan 11
    View PubMed
  5. Chu PL, Gigliotti JC, Cechova S, Bodonyi-Kovacs G, Chan F, Ralph DL, Howell N, Kalantari K, Klibanov AL, Carey RM, McDonough AA, Le TH. Renal Collectrin Protects against Salt-Sensitive Hypertension and Is Downregulated by Angiotensin II. J Am Soc Nephrol. 2017 Jun; 28 (6):1826-1837 Epub 2017 Jan 06
    View PubMed
  6. Gigliotti JC, Huang L, Bajwa A, Ye H, Mace EH, Hossack JA, Kalantari K, Inoue T, Rosin DL, Okusa MD. Ultrasound Modulates the Splenic Neuroimmune Axis in Attenuating AKI. J Am Soc Nephrol. 2015 Oct; 26 (10):2470-81 Epub 2015 Feb 02
    View PubMed
  7. Khan SF, Kalantari K. The use of iodinated contrast media in patients with end-stage renal disease. Semin Dial. 2014 Nov-Dec; 27 (6):607-10 Epub 2014 July 03
    View PubMed
  8. Baruch MC, Kalantari K, Gerdt DW, Adkins CM. Validation of the pulse decomposition analysis algorithm using central arterial blood pressure Biomedical Engineering. 2014; 13:96.
  9. Khan SF, Kalantari K. The use of iodinated contrast media in patients with end-stage renal disease Seminars in Dialysis. 2014; 27(6):607-610.
    View PubMed
  10. Vamenta-Morris H, Nishio-Lucar A, Rudy C, Kalantari K, Erdbruegger U. Role of endothelial and platelet-derived microparticles in hemodialysis access complications American Journal of Kidney Diseases. 2014; 63(5):A113.
  11. Gigliotti JC, Huang L, Ye H, Bajwa A, Chattrabhuti K, Lee s, Klibanov AL, Kalantari K, Rosin DL, Okusa MD. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. Journal of the American Society of Nephrology. 2013; 24(9):1451-1460.
  12. Kalantari K, Chang JN, Ronco C, Rosner MH. Assessment of intravascular volume status and volume responsiveness in critically ill patients. Kidney Int. 2013 Jun; 83 (6):1017-28 Epub 2013 Jan 09
    View PubMed
  13. Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif. 2013; 36 (1):29-36 Epub 2013 May 25
    View PubMed
  14. Kalantari K. The choice of vascular access for therapeutic apheresis Journal of Clinical Apheresis. 2012; 27(3):153-159.
  15. Okafor C, Kalantarinia K. Vascular access considerations for therapeutic apheresis procedures. Semin Dial. 2012 Mar-Apr; 25 (2):140-4 Epub 2011 Dec 16
    View PubMed
  16. Bagavant H, Kalantarinia K, Scindia Y, Deshmukh U. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice American Journal of Kidney Disease. 2011; 57(3):498-507.
  17. George SM, Kalantarinia K. The role of imaging in the management of cardiorenal syndrome International Journal of Nephrology. 2011; 2011:245241.
  18. Kalantarinia K, Belcik JT, Patrie JT, Wei K. Real-time measurement of renal blood flow in healthy subjects using contrast enhanced ultrasound. Am J Physiol Renal Physiol. 2009; 297:F1129-1134.
  19. Kalantarinia K. Novel imaging techniques in acute kidney injury Current Drug Targets. 2009; 10:1184-1189.
  20. Bakris G, Burgess E, Weir M, Davidai G, Koval S, AMADEO Study Investigators, Kalantarinia K.. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74 (3):364-9 Epub 2008 May 21
    View PubMed
  21. McCulloch M, Brooks H, Kalantarinia K. Isolated polyarticular septic arthritis: an atypical presentation of meningococcal infection. Am J Med Sci. 2008 Apr; 335 (4):323-6
    View PubMed
  22. Kalantarinia K. Ultrasound contrast agents in the study of kidney function in health and disease Drug Discovery Today Disease Mechanisms. 2007; 4(3):153-158.
  23. Liu J, Kalantarinia K, Rosner MH. Management of lipid abnormalities associated with end stage renal disease Seminars in Dialysis. 2006; 19(5):391-401.
    View PubMed
  24. Kalantarinia K, Okusa MD. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diab Rep. 2006 Feb; 6 (1):8-16
    View PubMed
  25. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003 Oct; 64 (4):1208-13
    View PubMed
  26. Kalantarinia K, Siragy HM. The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond. Curr Diab Rep. 2002 Oct; 2 (5):423-30
    View PubMed
PST-20536457